Jacobio Pharmaceuticals Group Co., Ltd. (Jacobio Pharma) disclosed that on 19 May 2026 it repurchased 179,400 ordinary shares on the Hong Kong Stock Exchange at prices between HKD 5.32 and HKD 5.38, for a total consideration of HKD 0.96 million (volume-weighted average price: HKD 5.37).

The buyback reduced outstanding shares (excluding treasury) by 0.02 % to 784.43 million, while treasury shares increased to 7.33 million. Total issued shares remained unchanged at 791.76 million.

Since the current mandate was approved on 10 June 2025, Jacobio Pharma has repurchased 4.31 million shares, representing 0.55 % of the share capital on the mandate date. The mandate authorises the company to repurchase up to 78.87 million shares.

Under Hong Kong Listing Rule 10.06(3)(a), the company is subject to a moratorium on issuing new shares or disposing of treasury shares until 18 June 2026.